Trial Profile
A Phase 2, Randomized, Open-Label Study of Azacitidine (Vidaza) vs MGCD0103 vs Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed AML [acute myeloid leukaemia] or Intermediate-2 or High-Risk MDS
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2019
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Mocetinostat (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors MethylGene; Mirati Therapeutics
- 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center).
- 13 May 2009 Actual patient number (6) added as reported by ClinicalTrials.gov
- 23 Jul 2008 Status changed from recruiting to in progress, as reported on clinicaltrials.gov